Diabetes/Metabolism Research and Reviews · 2014 · 25 citations · 33 references
MedicineEndocrinologyPharmacologyDiabetologyHuman NutritionMetabolic RegulationDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlPancreatic HormonesBeta FunctionBlood Glucose RegulationGlucagon-like PeptidesGlycemic BiomarkersPancreatic Beta-cell FunctionPancreatic Islet FunctionPostprandial Glucose RegulationVascular Biomarkers
BACKGROUND: The goal of this study was to investigate the effects of linagliptin compared with glimepiride on alpha and beta cell function and several vascular biomarkers after a standardized test meal. METHODS: Thirty-nine patients on metformin alone (age, 64 ± 7 years; duration of type 2 diabetes mellitus, 7.8 ± 4.5years, 27 male, 12 female; HbA1c , 57.2 ± 6.9 mmol/mol; mean ± SD) were randomized to receive linagliptin 5 mg (n = 19) or glimepiride (n = 20) for a study duration of 12 weeks. Glucagon-like peptide 1, blood glucose, insulin, intact proinsulin, glucagon, plasminogen activator inhibitor-1 (PAI-1), cyclic guanosinmonophosphat and asymetric dimethylarginin levels were measured in the fasting state and postprandial at 30-min intervals for a duration of 5 h. The areas under the curve (AUC0-300 min ) were calculated for group comparisons. RESULTS: HbA1c , fasting and postprandial glucose levels improved in both groups. An increase in postprandial insulin (22595 ± 5984 pmol/L*min), postprandial intact proinsulin (1359 ± 658 pmol/L*min), postprandial glucagon (317 ± 1136 pg/mL*min) and postprandial PAI-1 levels (863 ± 467 ng/mL*min) could be observed during treatment with glimepiride, whereas treatment with linagliptin was associated with a decrease in postprandial insulin (-8007 ± 4204 pmol/L*min), intact proinsulin (-1771 ± 426 pmol/L*min), postprandial glucagon (-1597 ± 1831 pg/mL*min) and PAI-1 levels (-410 ± 276 ng/mL*min). CONCLUSIONS: Despite an improvement in blood glucose control in both groups, linagliptin reduced postprandial insulin, proinsulin, glucagon and PAI-levels. These results indicate an improvement in postprandial alpha and beta cell function, as well as a reduced postprandial vascular risk profile during treatment with linagliptin.
33
Glucose Tolerance and Cardiovascular Mortality
Archives of Internal Medicine · 2001 · 1.4K citations · Full text
Medicine, Endocrinology, Diabetology +16
Matthieu Million, Marie Maraninchi, M. Henry et al. · International Journal of Obesity · 2011 · 654 citations · Full text
Franco Cavalot, Alessio Petrelli, M. Traversa et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 572 citations · Full text
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
James B. Meigs, Murray A. Mittleman, David M. Nathan et al. · PubMed · 2000 · 545 citations
Medicine, Endocrinology, Diabetology +11